1. An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1. Issue 4 (7th December 2020) Authors: Goss, Christopher H.; Jain, Raksha; Seibold, Wolfgang; Picard, Anne-Caroline; Hsu, Ming-Chi; Gupta, Abhya; Fajac, Isabelle Journal: ERJ open research Issue: Volume 6:Issue 4(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis. Issue 4 (7th December 2020) Authors: Nickolaus, Peter; Jung, Birgit; Sabater, Juan; Constant, Samuel; Gupta, Abhya Journal: ERJ open research Issue: Volume 6:Issue 4(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FEV1 recovery following methacholine challenge in asthma: Variability and comparison of methods. (February 2020) Authors: Singh, Dave; Khan, Naimat; Dean, James; Fowler, Andrew; Gupta, Abhya; Endriss, Verena; Iacono, Philippe; Disse, Bernd Journal: Pulmonary pharmacology & therapeutics Issue: Volume 60(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FOOTPRINTS study protocol: rationale and methodology of a 3-year longitudinal observational study to phenotype patients with COPD. Issue 3 (22nd March 2021) Authors: Crapo, James; Gupta, Abhya; Lynch, David A; Vogel-Claussen, Jens; Watz, Henrik; Turner, Alice M; Mroz, Robert M; Janssens, Wim; Ludwig-Sengpiel, Andrea; Beck, Markus; Langellier, Bérengère; Ittrich, Carina; Risse, Frank; Diefenbach, Claudia Journal: BMJ open Issue: Volume 11:Issue 3(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well‐Controlled Asthma. (13th June 2017) Authors: Fowler, Andy; Koenen, Rüdiger; Hilbert, James; Blatchford, Jon; Kappeler, Dominik; Benediktus, Ewald; Wood, Chester; Gupta, Abhya Journal: Journal of clinical pharmacology Issue: Volume 57:Number 11(2017) Page Start: 1444 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy of BI 671800, an oral CRTH2 antagonist, in poorly controlled asthma as sole controller and in the presence of inhaled corticosteroid treatment. (June 2015) Authors: Hall, Ian P.; Fowler, Andrew V.; Gupta, Abhya; Tetzlaff, Kay; Nivens, Michael C.; Sarno, Maria; Finnigan, Helen A.; Bateman, Eric D.; Rand Sutherland, E. Journal: Pulmonary pharmacology & therapeutics Issue: Volume 32(2015:Jun.) Page Start: 37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗